Navigation Links
Second U.S.-Egypt Collaborative Clinical Study Blocked by New York State Department of Health (NYSDOH), This Time on Complications of Diabetes
Date:9/15/2009

NEW YORK, Sept. 15 /PRNewswire/ -- A study exploring the healing of diabetic skin ulcers using topical oxygen/ozone gas mixtures could not proceed to completion and was now abandoned, according to Ozonics International, LLC, a veteran-owned biotechnology company engaged in the research and development of ozone-based medical therapies. "This fully scientific study, a world-first in its scope, was to be performed in Egypt, recruiting the collaboration of U.S. and Egyptian experts," said Gerard Sunnen, MD, Ozonics president.

Egypt has a diabetic population estimated at 5 million. The prevalence of diabetes is rising rapidly in the Middle East. 20% of diabetics develop skin lesions such as leg ulcers, and 15% of those will eventually require amputation. In the U.S., out of 24 million diabetics about 80,000 undergo lower limb amputations yearly.

"Pilot research studies have shown that topical oxygen/ozone treatment can dramatically reduce these amputation numbers," Dr. Sunnen emphasized, adding, "The FDA has already approved topical oxygen for skin healing in diabetes and vascular conditions. This proprietary technology adds a natural element's remarkable antimicrobial properties to accelerate wound resolution. No other antimicrobial can claim such wide range of action against the entire spectrum of wound-invading bacterial and fungal families, nor claim such unwavering defense against bacterial resistance, the bane of all antibiotics."

Other reported unique features of ozone include its ability to neutralize wound bacterial and fungal toxins - well known to inhibit healing - and to enhance local circulation via the activation of nitric oxide, in biochemical pathways shared by drugs like sildenafil (Viagra).

The study, named "Safety and efficacy of ozone therapy in the treatment of diabetic skin ulcers: A randomized double blind controlled clinical study," was to be sponsored by the University of Cairo, and endorsed by the National Research Centre, Cairo, the Egyptian National Institute for Diabetes and Endocrinology, and the Egyptian National Cancer Institute.

"The New York State Department of Health (NYSDOH), despite its denials, has long shown adversity to complementary medicine and to ozone-based medical therapies in particular, and research initiatives have suffered. Another U.S. medical ozone company, for example, had to back off from its groundbreaking clinical investigations on hepatitis C and now focuses on ozone disinfection of hospitals. NYSDOH's interference has proven to be a potent deal breaker. Inhibition of medical ozone development, possibly motivated by commercial interests, is done by discouraging potential business partners from collaborating with U.S. - based medical ozone companies and by discrediting U.S. researchers and entrepreneurs. Germany, Italy, Japan and Russia are consequently now far ahead of the U.S. in the development of these forward-looking biotechnologies."

Dr. Sunnen concluded, "Let us hope that the abandonment of this study will only be temporary and that research avenues will unlock. Diabetics need not suffer the travails of protracted skin ulcer treatments, often experienced as interminable. Amputations devastate the body and often profoundly demoralize patients. Looking into the future, research in oxygen/ozone topical therapies will find applications in all manner of acute and chronic wound care, including diabetic and pressure ulcers, circulatory skin lesions, post-surgical wounds, and complex accident and war wounds."

    Ozonics International, LLC
    Gerard Sunnen, MD, President
    200 East 33rd Street
    New York, NY 10016-4831
    Tel. 212-6790679 Fax 212-6798008
   http://www.ozonicsint.com
    Email: Ozonicsint@aol.com


'/>"/>
SOURCE Ozonics International, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
2. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Response Genetics Reports Second Quarter 2007 Financial Results
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Transgenomic, Inc. Reports Second Quarter 2007 Results
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Connecticut ... innovative, growing companies, today announced the launch of VentureClash , a $5 ... , “VentureClash looks to attract the best early-stage companies here in ...
(Date:4/27/2016)... ... , ... Shimadzu Scientific Instruments (SSI) will be showcasing a ... and Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for potency, ... by booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC testing, ...
(Date:4/27/2016)... British Virgin Islands (PRWEB) , ... April 27, ... ... Holding Company Ltd. (d/b/a Biohaven) is pleased to announce the appointment of John Tilton ... he was an Executive Director and one of the founding commercial leaders responsible ...
(Date:4/27/2016)... ... ... Global Stem Cells Group and the University of Santiago Biotechnology Lab ... initiatives for potential stem cell protocol management for 2016 – 2020. , In ... to establish a working agenda and foster initiatives to promote stem cell research and ...
Breaking Biology Technology:
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
(Date:3/9/2016)... PALM BEACH GARDENS, Fla. , March 9, ... of identity management authentication and enrollment solutions, today ... proven DigitalPersona ® Altus multi-factor ... enable IT and InfoSec managers to step-up security ... friction.  Washington, DC ...
(Date:3/3/2016)... and DE SOTO, Kansas , ... Stroke Detection Plus® to offer Oncimmune,s Early CDT®-Lung, ... and early detection of lung cancer Early ... unions and individuals. --> Early CDT®-Lung test ... individuals. --> Oncimmune, a leader in early ...
Breaking Biology News(10 mins):